Research programme: nitric oxide synthase gene therapy - Cardion/Boehringer Ingelheim
Latest Information Update: 02 Jul 2007
At a glance
- Originator Boehringer Ingelheim
- Class Gene therapies
- Mechanism of Action Nitric oxide synthase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Vascular disorders
Most Recent Events
- 14 Jun 2001 Preclinical development for Vascular disorders in Austria (Unknown route)
- 14 Jun 2001 New profile